Recent Updates
Recently added Catalysts
IVVD Positive Sentiment Score: 70/100

Invivyd to Host Conference Call Discussing Full Year 2022 Financial Results and Business Highlights

Key Takeaway: Invivyd, Inc. announced a conference call scheduled for March 23, 2023, to discuss its financial results for the year 2022 and key business developments. The call underscores the company's commitment to transparency with investors and stakeholders. Invivyd's mission centers on developing therapies to combat serious viral infections, leveraging advanced technology in antibody engineering. The event will provide insights into their progress and pipeline aimed at addressing high-need indications, including COVID-19 and influenza.

Market Sentiment Analysis

POSITIVE FACTORS

  • Invivyd is hosting a conference call to discuss its financial results and business highlights, showing transparency with investors.
  • The company is focused on delivering antibody-based therapies to protect vulnerable populations from viral diseases.
  • Invivyd has a robust pipeline of product candidates aimed at treating COVID-19 and other viral infections.

Full Press Release Details

WALTHAM, Mass., March 16, 2023 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) a clinical-stage biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious diseases, today announced that it will host a conference call on Thursday, March 23, 2023, at 4:30 p.m. ET to discuss its financial results for the full year ended December 31, 2022, and recent business highlights.
Listeners can register for the webcast via this link. Analysts wishing to participate in the question and answer session should use this link. A replay of the webcast will be available via the company’s investor website approximately two hours after the call’s conclusion. Those who plan on participating are advised to join 15 minutes prior to the start time.
Invivyd, Inc., is a biopharmaceutical company on a mission to rapidly and perpetually deliver antibody-based therapies that protect vulnerable people from the devastating consequences of circulating viral threats, beginning with SARS-CoV-2. Invivyd's technology works at the intersection of evolutionary virology, predictive modeling, and antibody engineering, and is designed to identify high-quality, long-lasting antibodies with a high barrier to viral escape. The company is generating a robust pipeline of product candidates which could be used in prevention or treatment of serious viral diseases, starting with COVID-19 and expanding into influenza and other high-need indications. Visit https://invivyd.com/ to learn more.
Kate Burdick, Evoke Canale
Chris Brinzey, ICR Westwicke

Frequently Asked Questions

When will Invivyd host its financial results conference call?

Invivyd will host its conference call on March 23, 2023, at 4:30 p.m. ET.

How can I listen to the Invivyd conference call?

Listeners can register for the webcast via the provided registration link.

What is Invivyd's main focus as a biopharmaceutical company?

Invivyd aims to protect vulnerable people from serious viral diseases using antibody-based therapies.

What types of diseases is Invivyd targeting with its therapies?

Invivyd's therapies target COVID-19, influenza, and other serious viral diseases.

Where can I find more information about Invivyd?

Additional information about Invivyd can be found on their website at invivyd.com.

Last updated: Mar 16, 2023